Karin Garvey


  • Chambers & Partners: United States, New York – Band 2: Antitrust: Mainly Plaintiff (2021-2023)
  • LawDragons: 500 Lead Plaintiff Financial Lawyers (2019-2024)
  • The Legal 500: United States – Antitrust: Civil Litigation/Class Actions: Plaintiff


Karin Garvey is a partner in Scott+Scott’s New York office focusing on antitrust and competition class action litigation. She represents victims of anticompetitive conduct in a wide variety of antitrust cases – from price fixing to monopolization to market allocation. She has been described as “an experienced and thoughtful litigator. She has been in the trenches and knows how to work through complex issues.”  Karin is regularly asked to participate on panels at class action and antitrust conferences, and she has published multiple articles on antitrust issues. Karin also serves as an adjunct faculty member in the trial advocacy program at Northwestern Pritzker School of Law.

Prior to moving to the plaintiffs’ side of the “v” almost 10 years ago, Karin spent 18 years on the defense side. She is therefore uniquely able to deploy the knowledge she gained as defense counsel to the strategic advantage of her clients on the plaintiffs’ side. Karin brings to Scott+Scott significant experience managing complex, multi-jurisdictional cases from initial case development through resolution. Karin has tried multiple antitrust cases to verdict, playing significant roles at those trials, and has briefed and argued appeals.


Karin has served as lead or co-lead counsel in the following antitrust class actions, among others:

  • In re Surescripts Antitrust Litigation 1:19-cv-06627 (N.D. Ill.) – alleging that health information technology company Surescripts, which provides e-prescription routing and eligibility services, monopolized the market for e-prescription services and, along with two other defendants, conspired to monopolize the market.
  • Fusion Elite All Stars v. Varsity Brands, LLC, No. 2:20-cv-02600 (W.D. Tenn.) – alleging monopolization and conspiracy to monopolize against the largest competition producer and apparel manufacturer in the market for All Star Cheer and the sport’s allegedly independent governing body.
  • In re Sensipar (Cinacalcet HCl) Antitrust Litigation, MDL No. 2895 (D. Del.) – alleging that a brand and a generic drug company entered into an anticompetitive agreement to eliminate competition for sales of Sensipar.


Karin was also appointed to the Plaintiff’s Steering Committee in In re Xyrem (Sodium Oxybate)
Antitrust Litigation
, No. 20-md-02966 (N.D. Cal.), a class action alleging, inter alia, that a brand drugmaker entered into anticompetitive pay-for-delay agreements with generic competitors, and In re Crop Inputs Antitrust Litigation, MDL 2993 (E.D. Mo.) a class action alleging, inter alia, that major manufacturers of crop inputs (e.g., seeds and pesticides) conspired to suppress competition and to fix prices.